Repligen announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory, based in Taoyuan City, Taiwan. Tantti has developed a portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids, and other large molecule biologics.
Tantti’s DuloCore® technology platform reportedly combines the high throughput performance of membranes with the rapid mass transfer of monoliths in a flexible bead format. Combined with AVIPure affinity ligands, the technology will provide additional performance advantages such as molecule selectivity, and increased efficiencies to address downstream bottleneck challenges and scalability concerns of manufacturers, according to Tony Hunt, CEO, Repligen, who added that the resins can be pre-packed for customers into Repligen’s OPUS columns.
“The addition of Tantti further strengthens our portfolio in the new modality space. Combining Tantti’s innovative bead technology with the content we are generating from Avitide [a Repligen company] will be game-changing,” Hunt said. “The industry needs high throughput and high-capacity purification products, and Tantti is the solution to delivering on this. We look forward to further developing and integrating their differentiated technology into our portfolio.”
“Repligen is the ideal partner for us to take this next step of growth and we look forward to working with our colleagues at Repligen to accelerate our market presence in bioprocessing,” said Joe Yang, CEO, Tantti.
The acquisition is expected to be completed in the fourth quarter of this year.